Types of Myeloproliferative Neoplasms (MPN)

The type of myeloproliferative neoplasm is based on whether too many red blood cells, white blood cells, or platelets are being made.

  • Chronic myelogenous leukemia (CML), occurs when immature cells that would be red blood cells, white blood cells, or platelets overtake the bone marrow and blood.
  • Essential thrombocythemia, occurs when too many platelets are made in the bone marrow.
  • Myelofibrosis (also called primary or chronic idiopathic myelofibrosis), occurs when abnormal blood cells and scarring build up within the bone marrow.
  • Polycythemia vera, occurs when too many red blood cells are formed in the bone marrow.
  • Chronic myeloproliferative disorders sometimes can become acute leukemia, in which too many immature abnormal white blood cells are made. This is a rare event.

Other, less common, myeloproliferative disorders include:

  • Chronic eosinophilic leukemia
  • Chronic neutrophilic leukemia
  • Mastocytosis
  • Myeloproliferative/myelodysplastic syndromes
  • Neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB OR FGFR1 genes

Statistics for Myeloproliferative Neoplasms

The incidence for each type of MPN varies.

  • Chronic myelogenous leukemia affects approximately 1.75 people per 100,000 per year.
  • Essential thrombocythemia affects 2.3 people per 100,000 per year.*
  • Myelofibrosis affects up to 1 person per 100,000 per year.*
  • Polycythemia vera affects up to 2.6 people per 100,000 per year.*

Reference: Anderson and McMullan, Curr Hematol Malig Rep. 2014 Aug 17. [Epub ahead of print] Epidemiology of MPN: What Do We Know?

Personalized Diagnostics at Penn Medicine

Penn Medicine's Center for Personalized Diagnostics (CPD) is paving the way for a new era of genomic medicine.

The CPD offers the highest volume of genome testing in the region, with a large volume of clinical and research samples to date. In clinical cases, disease-associated mutations have been reported in 75% of patient tests revealing results with prognostic and therapeutic significance.

Learn more about Penn Medicine's Center for Personalized Diagnostics.